VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 14, 2003--InNexus Biotechnology, Inc. (the "Company") announced today the scientific discovery that its SuperAntibodies can form an association (one antibody with the other, referred to as "dimerization") and that this appears to be related to their high potency in disease treatment. This discovery has enabled InNexus to file an additional patent that protects more uses of SuperAntibody Technology ("SAT") and will ultimately allow InNexus to work with more corporate partners. This discovery, recently published by InNexus's collaborators, Immpheron, Inc. of Lexington, Kentucky, has shown that monoclonal antibodies can be conjugated through carbohydrate linkage to a peptide capable of conferring a dimerizing ability to antibodies. The specific studies utilized antibodies to the B-cell receptor, present on normal and malignant B-cells, and demonstrated that such modified antibodies were superior at inducing apoptosis ("cell suicide") and in growth inhibition as well as binding better than an unmodified, native antibody - all key properties of therapeutically active antibodies.
The peer-reviewed publication referenced herein has been published and is posted on InNexus's website (www.innexusbiotech.com). The citation is: "Enhanced Tumor Targeting and Apoptosis Using Non-Covalent Antibody Homodimers," Y Zhao and H Kohler. J. Immunotherapy 25(5) :396-404, 2002.
Dr. Charles Morgan, President of InNexus commented, "This key scientific discovery is important for allowing InNexus to file for additional patent protection that enhances the intellectual property base for SAT. It will also enable SAT to appeal to more potential corporate partners and allow InNexus to develop antibodies for the treatment of additional forms of cancer and other life-threatening diseases."
InNexus has recently entered into an agreement with Corixa Corp (NASDAQ:CRXA - News) to use SAT with up to four of their antibodies currently in development.
InNexus is developing the next generation of therapeutic, monoclonal antibodies using its SuperAntibody Technology Platform. InNexus intends to apply this technology to improve the potency of existing antibody products while opening new markets and disease applications with other forms of SuperAntibodies. InNexus intends to develop the technology through partnerships with biotechnology and pharmaceutical companies while pursuing development of its own products for unmet medical needs. To learn more about InNexus please visit the Company's website: www.innexusbiotech.com.
On behalf of the Board of Directors of InNexus Biotechnology Inc. A. CHARLES MORGAN President
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.
The TSX Venture Exchange has neither approved or disapproved of this news release.
InNexus Biotechnology Inc. Investor Relations: Toll Free: 888-271-0788 or 866-990-8382 email@example.com or
InNexus Biotechnology Inc. Toll Free: A. Charles Morgan, 877-990-8382 Fax: 425-696-0068 firstname.lastname@example.org www.innexusbiotech.com
Source: InNexus Biotechnology Inc.